mg真人,mg真人在线

Ping Han

Assistant Researcher

  • Tel: +86-021-34204065
  • Email: esterhanping@sjtu.edu.cn
  • Address: Room 316, Life Science Building 2 School of Life Sciences and Biotechnology Shanghai Jiao Tong University 800 Dong Chuan Road, Shanghai, 200240,China

Selected Publications

  • ?  

    Ping Han, Qiang Dai, Lilv Fan, Hao Lin, Xiaoqing Zhang, Fanlin Li, Xuanming Yang*, Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance, Frontiers in Immunology, 2019, 10 (251), doi.org/10.3389/fimmu.2019.00251

    ?  

    Han, P. and Yang, X. M.(2019). Analyzing Cytokines Production during T Cell Activation by Flow Cytometry Intracellular Staining. Bio-101 e1010314. Doi: 10.21769/BioProtoc.1010314.

    ?  

    Zhiwen Yin#, Jiyan Hou, Ping Han*, Xuanming Yang*, IFN-α/anti-PD-L1 fusion protein activates tumor specific CD8(+) T lymphocyte responses for anti-tumor efficacy. Current Immunology, 2019, 39(1): 1-7

    ?  

    P. Han#, S. Liu#, M. Zhang#, J. Zhao, Y. Wang, G. Wu, et al. Inhibition of Spinal Interlukin-33/ST2 Signaling and Downstream ERK and JNK Pathways in Electroacupuncture Analgesia in Formalin Mice. PLoS One 2015, 10:e0129576. 

    ?  

    P. Han, J. Zhao, S.B. Liu, C.J. Yang, Y.Q. Wang, G.C. Wu, et al. Interleukin-33 mediates formalin-induced inflammatory pain in mice. Neuroscience 2013, 241:59-66. 

  • ?  

    P. Han, W.L. Mi, Y.Q. Wang. Research progress on interleukin-33 and its roles in the central nervous system. Neurosci Bull 2011, 27:351-357. 

    ?  

    Wang H, Han P, Qi X, Li F, Li M, Fan L, Zhang H, Zhang X, Yang X.Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis. Cancers (Basel). 2021; 13(2).

    ?  

     Li M, Xu Y, Liang J, Lin H, Qi X, Li F, Han P, Gao Y, Yang X. USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis. Mol Ther. 2021.

    ?  

    Dai Q, Han P, Qi X, Li F, Li M, Fan L, Zhang H, Zhang X, Yang X.4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells. Front Immunol. 2020; 11:539654.

    ?  

    Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X,Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun, 2019,20;10(1):2141. doi: 10.1038/s41467-019-10088-1.